Locus Biosciences
locus-bio.com
Actively hiring
Drug Discovery
As featured in
View 2 jobs
Claim pageClaim
Follow
Overview
Connections
News
Technologies
Salaries
Products
People
Growth
Offices
Jobs
Financials
Funding and backers
Total raised
$49.8M
7 rounds on record
Latest round
$23.9M
Venture round · Jan 2024 · 2 yr ago
Team
46
US Form 5500 (plan participants) · Dec 2025 · -4% in a year
Hiring now
2
open roles
Backers
1
Abstract Ventures
The money's age
Long since its last round
33 months since the last round · hiring slowed
Momentum
10/100
a new city
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jan 26, 2024
Raised a round Venture round $23.9M
Jan 28, 2022
Raised a round Venture round $10.6M · SEC Form D
Apr 8, 2020
Took on debt financing $20M · SEC Form D
Jul 6, 2018
Raised a round Venture round $7M · SEC Form D
Sep 18, 2017
Raised a round Venture round $7M · SEC Form D
Dec 1, 2016
Took on debt financing $350k · SEC Form D
Jan 13, 2016
Raised a round Venture round $1.3M · SEC Form D
2015
Founded
Tractionpublic signals, read monthly
Web presence
top 3%
of 133.2M domains by links, Common Crawl
Hacker News stories
1
best: 1 points
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Jan 2024 | $23.9M | — | locus-bio.com |
| Venture round | Jan 2022 | $10.6M | — | SEC Form D |
| Debt Financing | Apr 2020 | $20M | — | SEC Form D |
| Venture round | Jul 2018 | $7M | — | SEC Form D |
| Venture round | Sep 2017 | $7M | — | SEC Form D |
| Debt Financing | Dec 2016 | $350k | — | SEC Form D |
| Venture round | Jan 2016 | $1.3M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | LOCUS BIOSCIENCES, INC. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Nick TaylorExecutive OfficerSEC Form D
Paul GarofoloExecutive Officer, DirectorSEC Form D
David OusteroutExecutive OfficerSEC Form D
Joseph NixonExecutive OfficerSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Regor combines a cutting-edge drug discovery engine with target validation and optimization for preclinical candidates in metabolism…
From Code to Cure: Etcembly combines cutting-edge artificial intelligence and bioengineering to accelerate therapeutic innovation and…
Treeline Biosciences is a biotechnology company developing small-molecule medicines for cancer and immune diseases.
AllRock Bio is leveraging extensive expertise from drug development to commercialization. AllRock Bio’s team is dedicated to advancing…
Gandeeva Therapeutics is a precision medicine company leveraging cryo-EM and machine learning for drug discovery.
CoSyne Therapeutics is a vertically integrated AI drug discovery company aiming to bring speed to precision medicine through polymathic AI…
Visa sponsorship
2
H-1B filings in 12 months
$68k
Median offered salary
2
Open roles in United States
Who they sponsor
Biochemists and biophysicists
1
Other mathematical science occupations
1
In the register as LOCUS BIOSCIENCES, INC., Morrisville, NC
Other sponsors in the same field
Genentech 
Exelixis 
Schrodinger 
Generate:Biomedicines
See 2 open roles Alert me
US Department of Labor · latest filing Apr 28, 2026 · Visa details by country
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Abstract VenturesVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Locus Biosciences Awarded $3.3 Million from NIH to Support Clinical Trial of AI-Designed Bacteriophage Therapy for Pneumonia caused by Antibiotic Resistant Bacteria
MORRISVILLE, N.C.--(BUSINESS WIRE)--Locus Biosciences today announced a contract award from the National Institute of Allergy and Infectious Diseases
Read more
Report
Locus Biosciences Awarded $3.3 Million from NIH to Support Clinical Trial of AI-Designed Bacteriophage Therapy for Pneumonia caused by Antibiotic Resistant Bacteria
Locus Biosciences today announced a contract award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of...
Read more
Report
Locus Biosciences Enters Research Collaboration to Develop Precision Antibacterial Therapies for Ophthalmic Infections
Collaboration to develop engineered bacteriophage therapeutics targeting bacterial pathogens responsible for serious eye infections Research Triangle Park, North Carolina, October 28, 2025 - Locus Biosciences, Inc. ("Locus"), a clinical-stage biotechnolog
Read more
Report
Locus Biosciences
The Nature Index tracks the affiliations of scientific articles from high-quality publications. The research profile for Locus Biosciences reflects the research output of authors from Locus Biosciences who published articles in the 145 journals included i
Read more
Report
Inside LOCUS AI - How the team uses artificial intelligence
Locus deploys three different flavors of AI and our drug development efforts. The first is machine learning, which I'll get to in more depth later, but briefly it allows us to use our high throughput automation capability to measure the outcomes of each o
Read more
Report
Crispr-Enhanced Viruses Are Being Deployed Against UTIs
With antibiotics losing their effectiveness, one company is turning to gene editing and bacteriophages-viruses that infect bacteria-to combat infections. The post Crispr-Enhanced Viruses Are Being Deployed Against UTIs appeared first on Locus Bioscience.
Read more
Report
Crispr-Enhanced Viruses Are Being Deployed Against UTIs
With antibiotics losing their effectiveness, one company is turning to gene editing and bacteriophages-viruses that infect bacteria-to combat infections.
Read more
Report
Phage Therapy's Neglected Potential Is Finally Being Realized
Technologies for generating superphages and optimizing phage cocktails are poised to overcome antibiotic resistance and resolve microbiome dysbiosis The post Phage Therapy's Neglected Potential Is Finally Being Realized appeared first on Locus Bioscience.
Read more
Report
Locus Biosciences Announces Positive Results from Part 1 of ELIMINATE Phase 2 Trial of the Engineered Bacteriophage Therapy LBP-EC01 Published in The Lancet Infectious Diseases
Primary and secondary objectives were met in the open-label randomized Part 1 of the clinical trial to treat uncomplicated UTIs caused by antibiotic-resistant E. coli Dosing has begun in Part 2, the controlled, double-blind portion of the trial triggered
Read more
Report
Antimicrobial Resistance: Multiple Threats, Multiple Responses
The post Antimicrobial Resistance: Multiple Threats, Multiple Responses appeared first on Locus Bioscience.
Read more
Report
Show more news
Tech stack
Technologies named in job postings at Locus Biosciences over the last 12 months, by layer, with the share of postings for each.
Technologies in use
8
Postings analysed
1
Stack modernity
48/100
Practices & domains
Bioreactors
CAPA
Chromatography
GLP
GMP
Next-Generation Sequencing
Design of Experiments
PCR
Sign in to see how your skills match this stack
Sign In
People
Nick Taylor
Executive Officer
Paul Garofolo
Executive Officer, Director
David Ousterout
Executive Officer
Joseph Nixon
Executive Officer
Chuck Bramlage
Director
Geoffrey Glass
Director
Bary Bailey
Director
David Johnston
Director
Stuart Peterson
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Growth
Hiring Momentum
48/100
Stable
Open positions
2
0 opened / 0 closed in 30 days
ATS activity
Every ~6 hours
Today
Hiring Dynamics
0%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Management
50% ▼
Science & Research
50% ▼
Activity Timeline
Added CAPA to stack
Oct 2026
Added PCR to stack
Oct 2026
Added Next-Generation Sequencing to stack
Oct 2026
Added GMP to stack
Oct 2026
Added GLP to stack
Oct 2026
Added Design of Experiments to stack
Oct 2026
Added Chromatography to stack
Oct 2026
Added Bioreactors to stack
Oct 2026
New location: Research Triangle Park
Oct 2026
New location: United States
Sep 2026
Removed Rest API from stack
Sep 2026
Added Rest API to stack
Sep 2026
Offices
Where the company hires and what each office is for
Cities
2
Hiring now
1
Countries
1
Busiest office
Research Triangle Park
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
Morrisville
United States
HQ
Partner With Us
523 Davis Drive Suite 350, Morrisville NC 27560
Research Triangle Park
United States
Engineering / R&D
2 open roles 50% engineering 50-200 est. staff
hires for Management, Science & Research
Jobs
≈ $55k – $115k per year (Estimated) · In office · Research Triangle Park
PCR
Next-Generation Sequencing
Chromatography
Bioreactors
GMP
GLP
Design of Experiments
MedTech
CAPA
Apply
≈ $96k – $179k per year (Estimated) · In office · 5+ years exp · Research Triangle Park
Microsoft Project
Life Sciences
GMP
Apply
Financials
Total raised
$70.2M
Latest round
Venture - Series Unknown
Funding rounds
7
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2024 | $23.9M | Details |
| Venture - Series Unknown | 2022 | $10.6M | Details |
| Debt Financing | 2020 | $20M | Details |
| Venture - Series Unknown | 2018 | $7M | Details |
| Venture - Series Unknown | 2017 | $7M | Details |
| Debt Financing | 2016 | $350k | Details |
| Venture - Series Unknown | 2016 | $1.3M | Details |